Enterococcus faecium
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | 37 |
50 | 34 | 66 | 45 |
Azithromycin | - |
- | - |
- | - |
Aztreonam | - |
- | - |
- | - |
Cefazolin | - |
- | -
- |
- |
|
Cefepime | - |
- | -
- |
- |
|
Ceftazidime | - |
- | - |
- | - |
Ceftriaxone | - |
- | - |
- | - |
Cefuroxime | - |
- | -
- |
- |
|
Ciprofloxacin | 20 |
31 | 20 |
24 | 25 |
Clarithromycin | - |
- | - |
- | - |
Clindamycin | - |
- | - |
- | - |
Doxycycline | 63 |
61 | 59 |
38 | 41 |
Erythromycin | - |
- | - |
- | - |
Gentamicin | 63S |
96S | 82S |
91S | 96S |
Imipenem | +/- |
+/- | +/- |
+/- | +/- |
Levofloxacin | 27 | 43 | 28 | 29 | 29 |
Meropenem | - | - | - | - | - |
Moxifloxacin | +/- | +/- | +/- | +/- | +/- |
Nitrofurantoin | 58& | 65& | 45& | 50& | 53& |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | 35 | 50 | 32 | 66 | 43 |
Piperacillin | +/- | +/- | +/- | +/- | +/- |
Piperacillin/tazo | +/- | +/- | +/- | +/- | +/- |
Ticarcillin/Clav | -* | -* | -* | -* | -* |
Tobramycin | - | - | - | - | - |
TMP/SMX | - | - | - | - | - |
Unasyn/Aug | |||||
Vancomycin | 53 | 70 | 51 | 56 | 63 |
# Tested | 66 | 54 | 99 | 66 | 51 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections